ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	ClinicalTrials.gov
Last refreshed on:	19 February 2015
Main ID:	NCT00004323
Date of registration:	18/10/1999
Prospective Registration:	No
Primary sponsor:	National Center for Research Resources (NCRR)
Public title:	Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
Scientific title:
Date of first enrolment:	February 1995
Target sample size:	10
Recruitment status:	Completed
URL:	http://clinicaltrials.gov/show/NCT00004323
Study type:	Interventional
Study design:	Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
Phase:	Phase 2

Countries of recruitment
United States

Contacts

Name:	Mary Carol Territo
Address:
Telephone:
Email:
Affiliation:	University of California, Los Angeles

Key inclusion & exclusion criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Severe aplastic anemia with 2 of the following criteria:
Polymorphonuclear neutrophils no more than 0.5 x 10 to the ninth/L Platelets no more than
20 x 10 to the ninth/L Reticulocytes no more than 30 x 10 to the ninth/L Hypocellular bone
marrow Related donor aged 6 weeks or more, matching at least 4 of 6 HLA A, B, and DRI
loci, as follows: HLA-identical family member for patients aged less than 40 years
HLA-nonidentical family member for patients aged less than 55 years failing antithymocyte
globulin or other immunosuppressive therapy The following eligible for transplantation as
initial therapy: Patients aged less than 40 years with HLA-matched donor Patients aged
40-45 years with HLA-identical donor No neoplastic or preneoplastic evolution --Patient
Characteristics-- Age: Under 40 (55 if ATG failure) Hepatic: No severe liver dysfunction
Renal: No severe renal dysfunction Cardiovascular: No severe cardiac dysfunction Other: No
other organ dysfunction that would compromise survival after transplant No HIV infection

Age minimum: N/A
Age maximum: 55 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Aplastic Anemia

Intervention(s)

Drug: cyclosporine

Drug: methylprednisolone

Drug: cyclophosphamide

Drug: anti-thymocyte globulin

Drug: methotrexate

Drug: mesna

Primary Outcome(s)

Secondary Outcome(s)

Secondary ID(s)

UCLA-94020602

199/11863

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

University of California, Los Angeles

Ethics review

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.